Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Liposome Combined With Albumin Paclitaxel and Gemcitabine as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

NCT06513455 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT06513455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Liposome Combined With Albumin Paclitaxel and Gemcitabine as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Harbin Medical University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2024
Completion date
December 31, 2027
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer